Comparative Clinical Assessment of Efficacy of Shataputi Abhrak Bhasma Along With Chausasti Pippali as an Adjuvant to AKT in Pulmonary TB
Article pdf download
Publication Certificate

Keywords

TB, DOTS, Abhrak Bhasma, Chausasti Pippali

How to Cite

Kokane, V., & Pawar, V. (2019). Comparative Clinical Assessment of Efficacy of Shataputi Abhrak Bhasma Along With Chausasti Pippali as an Adjuvant to AKT in Pulmonary TB. Ayurline: IJ-RIM, 3(04). Retrieved from http://ayurline.in/index.php/ayurline/article/view/275

Abstract

Worldwide, tuberculosis (TB) is one of the top 10 causes of death, and the leading cause from a single infectious agent. It has been reported that millions of people continue to fall sick with TB each year. Since 1994, with endorsement from WHO; DOTS, Directly Observed Treatment Short-course strategy has been implemented worldwide for control of TB. However, the increasing incidence of TB suggests the need for newer medicines, especially from Ayurveda. Rajayakshma has been correlated with pulmonary tuberculosis due to a great deal of similarities in their manifestations. Abhraka Bhasma and Chausasti Pippali are widely used by Ayurvedic physicians for the treatment of various respiratory diseases. This study was designed to elucidate their anti-tubercular efficacy as an adjuvant to DOTS therapy. The study was conducted on 60 patients diagnosed with Pulmonary TB and showing signs and symptoms of Rajayakshma. They were divided into two groups. The study duration was two months. As per the observations, it was seen that, though both groups were receiving anti-tubercular drugs; the response in the group B patients (DOTS with Shataputi Abhraka Bhasma and Chausasti Pippali) was comparatively better and earlier in some of the symptoms studied. The subjective feeling of the sense of well being was enhanced and reported earlier by the patients of Group B. It can be concluded that co-administration of Shataputi Abhrak Bhasma and Chausasti Pippali along with AKT provided better outcome.

Article pdf download
Publication Certificate

References

1.Global tuberculosis report 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.
2.Agnivesha, Charaka Samhita elaborated by Charaka & Drudhabala with Ayurveda-Deepika Commentary by Chakrarapanidatta, edited by Dr. Brahmanand Tripathi, Varanasi, Choukhambha Surbharati Prakashan, Reprinted 2013, Chikitsa sthana chapter 8, verse no.13
3.Chaudhuri AD. Recent changes in technical and operational guidelines for tuberculosis control programme in India - 2016: A paradigm shift in tuberculosis control. J Assoc Chest Physicians [serial online] 2017 [cited 2019 Sep 3];5:1-9. Available from: http://www.jacpjournal.org/text.asp?2017/5/1/1/196644
4.Pal, D., Sahu, C. K., & Haldar, A. (2014). Bhasma : The ancient Indian nanomedicine. Journal of advanced pharmaceutical technology & research, 5(1), 4–12. doi:10.4103/2231-4040.126980
5.Yogesh pandey et al. Pippali Vardhamana Rasayana Is A Safe And Effective Adjuvant To Dots In Treatment Of Pulmonary Tuberculosis. World Journal Of Ayurveda Science VOL II ISSUE III MAY 2017e-ISSN 2456-0227.
6.Lin HH, Ezzati M, Chang HY, Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: Prospective cohort study. Am J Respir Crit Care Med. 2009;180:475–80. [PubMed: 19542475]

I  declare (on behalf of me and my co-authors) that the submitted manuscript titled has not previously been published and is not currently being considered elsewhere for publication in another journal and that I am (we are) the sole owner(s) of the manuscript thereof and of all rights, title, and interest therein. All agreed to the terms and conditions, Privacy Policy, which is declared on Journal Website http://www.ayurline.in and online filled (uploaded) form

Downloads

Download data is not yet available.